Amicus Therapeutics to Announce First Quarter 2011 Financial Results on May 4, 2011

/ Source: GlobeNewswire

CRANBURY, N.J., April 27, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced that management will host a conference call and live audio webcast on Wednesday, May 4, 2011 to discuss financial results for the first quarter ended March 31, 2011.

Interested participants and investors may access the conference call at 5 p.m. EDT by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at 8 p.m. EDT today. Access numbers for this replay are 800-642-1687 (U.S./Canada) and 706-645-9291 (international); participant code 62822099.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program Amigal(tm) (migalastat HCl) is in Phase 3 for the treatment of Fabry disease.

FOLD-G

CONTACT: Investors/Media: Sara Pellegrino spellegrino@amicustherapeutics.com (609) 662-5044